Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer

Antoniou, D.; Pavlakou, Georgia; Stathopoulos, George P.; Karydis, Ioannis; Chondrou, Evangelia; Papageorgiou, C.; Dariotaki, Fotini; Chaimala, Dimitra; Veslemes, M.

doi:10.1016/j.lungcan.2006.03.015

Cited by 64 publications

(60 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma levels of D-dimer may strongly predict survival and response to chemotherapy in lung cancer patients. Antoniou et al (18) measured plasma D-dimer levels in lung cancer patients before, during and after chemotherapy. They indicated that 73.7% of the patients with complete or partial response showed a reduction in plasma D-dimer levels and 68.8% of the patients with progressive disease showed increased D-dimer levels.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Plasma D-Dimer Levels in Patients with Lung Cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Plasma D-Dimer Levels in Patients with Lung Cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Patients with malignancy may present with various circulatory markers of prothrombotic and hemostatic activation which may be related with tumor growth and distant metastasis (Antoniou et al, 2006;Sekhon et al, 2006;Kirwan et al, 2008). In clinical oncology practice, physicians have observed hemostatic disorders with or without arterial or venous thrombotic events in patients with malignancies.…”

Section: Discussionmentioning

confidence: 99%

“…Several small studies have reported that plasma D-dimer levels increase in early-stage and advanced malignancies of the lung, breast, and colorectal region (Oya et al, 2001;Antoniou et al, 2006;Sekhon et al, 2006;Kirwan et al, 2008). Additionally, limited previous studies have demonstrated that plasma D-dimer levels predict the prognosis and response of systemic treatment in patients with breast, lung, and ovary cancer (Antoniou et al, 2006;Sekhon et al, 2006;Kirwan et al, 2008;Yoshiki et al, 2010;Komurcuoglu et al, 2011;Yamamato et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Predictive Value of Baseline Plasma D-dimers for Chemotherapy-induced Thrombocytopenia in Patients with Stage III Colon Cancer: A Pilot Study

Tanrıverdi

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…These patients did not have any treatment at the moment to be included in the study. The voluntaries with medium or high risk of LC were invited to evaluate the LC risk with AQC in induced sputum and with the tumour marker DR70 in serum [24][25][26][27][28]. According to AQC and DR70 results, the voluntaries were classified under three categories of LC risk (low, medium and high).…”

Section: Populationmentioning

confidence: 99%

Circulating Free DNA in Serum and Genomic Alterations of Lung Cancer Patients and High Risk Individuals Exposed to Environmental Pollution

Marta¹,

T²,

Ulises³

et al. 2017

Biomark J

View full text Add to dashboard Cite

The implementation of early-detection technologies and prognostic biomarkers are imperative, specifically in cities highly exposed to environmental carcinogens, such as PAHs and Arsenic. This study proposed to evaluate cfDNA levels and determine CNAs in serum cfDNA in LC and PNL patients. The study enrolled a total of 107 people, from the Metropolitan (N=51) and Antofagasta (N=56) regions, with medium or high LC risk. The cfDNA was isolated from serum aliquots using Qiagen QIAamp DNA mini kit. HMMs analysis in cfDNA, was used as a probabilistic model to determine an unknown sequence and defined Minimal Common Regions (MCRs) of recurring DNA gains and losses. This study shows that cfDNA levels increased during malignancy of LC but not significantly during premalignant lesions or pre-invasive stages. The cfDNA could be used as a complementary tool to prognosis and evolution of LC, with high precision (specificity of 87.3% and PNV of 76.4%). Additionally, the cfDNA carry some chromosomal aberrations related with the lung tumorigenesis process that could be used to confirm a suspected case of LC. Within these alterations our results suggest the loss of specific chromosomic fragments, contain genes related with inflammation response (SERPING1), humoral immune response (IGCK), innate immunity and epithelial integrity (CTNN1), tumor suppressor (MAP2K4, DMTF1 and ABCB4), and response to oxidative stress (COX10). In conclusion, these biomarkers in cfDNA, could have a great potential as screening methods in population with high risk for LC.

show abstract

Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer

Cited by 64 publications

References 22 publications

Prognostic Significance of Plasma D-Dimer Levels in Patients with Lung Cancer

Prognostic Significance of Plasma D-Dimer Levels in Patients with Lung Cancer

Predictive Value of Baseline Plasma D-dimers for Chemotherapy-induced Thrombocytopenia in Patients with Stage III Colon Cancer: A Pilot Study

Circulating Free DNA in Serum and Genomic Alterations of Lung Cancer Patients and High Risk Individuals Exposed to Environmental Pollution

Contact Info

Product

Resources

About